Today: 3 July 2026
Browse Category

Dividends 26 February 2026 - 5 March 2026

ANZ shifts 2026 results and dividend dates, resetting the calendar investors watch

ANZ shifts 2026 results and dividend dates, resetting the calendar investors watch

ANZ Group Holdings Limited said Wednesday it’s moving up its FY26 half-year results release to May 1, instead of the previously scheduled May 7, and has also tweaked elements of its interim dividend schedule. Details appeared in an exchange filing. The date on the calendar isn’t just a formality—results day is when the bank reveals its profit, capital position, and the next payout. Trading often gets volatile around those announcements. Investors eyeing the interim dividend are watching the clock; when you buy in can spell the difference between a payout and missing out.
5 March 2026
··
Itaú Unibanco sets March 10 cash payout after selling “bonus share” fractions on B3

Itaú Unibanco sets March 10 cash payout after selling “bonus share” fractions on B3

Itau Unibanco Holding SA plans to distribute proceeds from the sale of fractional share entitlements—generated by an earlier bonus share issue—on March 10, the Brazilian bank disclosed Tuesday in a filing with U.S. securities regulators. The step is procedural. Still, it comes as investors keep an eye on how Brazil’s largest banks juggle payouts and capital housekeeping, following a run of bonus issues, recurring distributions, and buybacks throughout the sector.
4 March 2026
··
1 … 3 4 5 6 7 … 44

Stock Market Today

  • Asahi Kasei (TSE:3407) wraps up ¥17.86bn buyback, highlights pharma tech scale-up
    July 3, 2026, 4:32 PM EDT. Asahi Kasei (TSE:3407) finished a ¥17.86 billion buyback, taking in 0.75% of its shares and signaling a focus on returns for shareholders. Peptistar has now launched Asahi Kasei's FO-MD system at the plant level, putting its pharmaceutical concentration tech into real-world production. This push could drive earnings through healthcare and process solutions, adding to its main battery and hydrogen businesses. Some risks remain for executing FO-MD and AK1940 at scale. The stock has moved up, but some see valuation still lagging-with fair value estimates pointing to a possible double from here. The story here is tighter capital discipline and a bigger bet on new technology.
Go toTop